$-0.31 EPS Expected for VBI Vaccines Inc. (VBV)
March 12, 2018 – By Kurt Siggers
Analysts expect VBI Vaccines Inc. (TSE:VBV) to report $-0.31 EPS on March, 23.They anticipate $0.07 EPS change or 29.17 % from last quarter’s $-0.24 EPS. After having $-0.30 EPS previously, VBI Vaccines Inc.’s analysts see 3.33 % EPS growth. The stock decreased 0.96% or $0.05 during the last trading session, reaching $5.14. About 875 shares traded. VBI Vaccines Inc. (TSE:VBV) has 0.00% since March 12, 2017 and is . It has underperformed by 16.70% the S&P500.
VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $327.26 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.
More important recent VBI Vaccines Inc. (TSE:VBV) news were published by: Globenewswire.com which released: “VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum” on November 02, 2017, also Streetinsider.com published article titled: “Form 8-K VBI Vaccines Inc/BC For: Feb 19”, Streetinsider.com published: “VBI Vaccines (VBIV) Prices Common Stock Offerings at $3.05/Share” on October 26, 2017. More interesting news about VBI Vaccines Inc. (TSE:VBV) was released by: Seekingalpha.com and their article: “VBI Vaccines Might Be A Recovery Play After A Dip” with publication date: August 18, 2017.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.